MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Milestone Scientific Balance Sheet 2011-2025 | MLSS
Annual Balance Sheet Milestone Scientific
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-3.09 M | -2.87 M | -8.61 M | -14.7 M | -14.2 M | -1.5 M | -743 K | -2.64 M | -3.6 M | -4.19 M | -10.4 M | -1.15 M | 285 K | 351 K |
Long Term Debt |
54.7 K | 434 | 10.7 K | 20.1 K | - | - | - | - | - | - | - | - | 450 K | 447 K |
Long Term Debt Current |
116 K | 103 K | 91.7 K | 81 K | 72 K | 16 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | 1.4 M | - | - | - | 1 | 450 K | 447 K |
Total Current Liabilities |
3.74 M | 3.08 M | 3.3 M | 3.1 M | 2.88 M | 4.93 M | 4.87 M | 6.73 M | 5.01 M | - | 2.44 M | 2.54 M | 3.27 M | 4.61 M |
Total Liabilities |
3.96 M | 3.36 M | 3.7 M | 3.59 M | 3.46 M | 4.93 M | 4.87 M | 8.13 M | 5.01 M | 3.64 M | 2.44 M | 2.54 M | 3.72 M | 5.06 M |
Deferred Revenue |
- | - | - | - | - | 340 K | 522 K | 2.48 M | 1 M | - | - | - | - | - |
Retained Earnings |
-128 M | -123 M | -116 M | -108 M | - | -93.5 M | -86 M | -78.6 M | -73.4 M | -67.4 M | -62 M | -60.3 M | -61.7 M | -60.9 M |
Total Assets |
9.8 M | 11.4 M | 13.7 M | 19.8 M | 19.6 M | 6.56 M | 6.4 M | 15.6 M | 13.6 M | 12.8 M | 17.5 M | 8.06 M | 5.66 M | 6.99 M |
Cash and Cash Equivalents |
3.26 M | 2.98 M | 8.72 M | 14.8 M | 14.2 M | 1.52 M | 743 K | 2.64 M | 3.6 M | 4.19 M | 10.4 M | 1.15 M | 165 K | 96.3 K |
Book Value |
5.83 M | 8.01 M | 10 M | 16.2 M | 16.1 M | 1.63 M | 1.53 M | 7.5 M | 8.54 M | 9.17 M | 15 M | 5.52 M | 1.94 M | 1.94 M |
Total Shareholders Equity |
5.83 M | 8.01 M | 10.2 M | 16.4 M | 16.2 M | 1.7 M | 1.54 M | 7.24 M | 8.5 M | 10.3 M | 14.6 M | 5.52 M | 1.94 M | 1.94 M |
All numbers in USD currency
Quarterly Balance Sheet Milestone Scientific
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
34.2 K | 41 K | 47.8 K | 54.7 K | - | - | - | 434 | 3.09 K | 5.68 K | 8.22 K | 10.7 K | 13.1 K | 15.5 K | 17.8 K | 20.1 K | 22.3 K | 24.4 K | 24.4 K | 28.6 K | 28.6 K | 28.6 K | 28.6 K | - | - | - | 15.9 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 450 K | 450 K | 450 K | 450 K | 450 K | 450 K | 447 K | 447 K | 447 K | 447 K |
Total Liabilities |
5.94 M | 4.71 M | 4.63 M | 3.96 M | 3.95 M | 4.05 M | 3.89 M | 3.36 M | 3.59 M | 3.45 M | 3.02 M | 3.7 M | 4.1 M | 3.84 M | 4.3 M | 3.59 M | 4.05 M | 3.49 M | 3.6 M | 3.46 M | 3.46 M | 3.46 M | 3.46 M | 4.93 M | 4.93 M | 4.93 M | 4.93 M | 4.87 M | 4.87 M | 4.87 M | 4.87 M | 8.13 M | 8.13 M | 8.13 M | 8.13 M | 5.65 M | 5.65 M | 5.65 M | - | - | - | - | - | 2.49 M | - | - | - | 2.54 M | 2.55 M | 2.98 M | 3.41 M | 3.72 M | - | 3.72 M | 3.72 M | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 50 K | 100 K | 1.26 M | 2.82 M | 1.73 M | 1.73 M | 713 K | 1.73 M | 1.73 M | 1 M | 1 M | 1 M | 1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-133 M | -132 M | -130 M | -128 M | -126 M | -125 M | -125 M | -123 M | -121 M | -120 M | -118 M | -116 M | -114 M | -112 M | -110 M | -108 M | -107 M | -105 M | -102 M | -101 M | -101 M | -101 M | -101 M | -93.5 M | -93.5 M | -93.5 M | -93.5 M | -86 M | -86 M | -86 M | -86 M | -78.6 M | -78.6 M | -78.6 M | -78.6 M | -73.4 M | -73.4 M | -73.4 M | -73.4 M | -67.4 M | -67.4 M | -67.4 M | -67.4 M | -62 M | -62 M | -62 M | -62 M | -60.3 M | -60.3 M | -60.3 M | -60.3 M | -61.7 M | -61.7 M | -61.7 M | -61.7 M | -60.9 M | -60.9 M | -60.9 M | -60.9 M |
Total Assets |
8.49 M | 8.05 M | 9.09 M | 9.8 M | 11.2 M | 12 M | 11.4 M | 11.4 M | 11.4 M | 11.4 M | 12.3 M | 13.7 M | 15.3 M | 13.7 M | 19.1 M | 19.8 M | 20.1 M | 21.1 M | 22.6 M | 19.6 M | 19.6 M | 19.6 M | 19.6 M | 6.56 M | 6.56 M | 6.56 M | 6.56 M | 6.4 M | 6.4 M | 6.4 M | 6.4 M | 15.6 M | 15.6 M | 15.6 M | 15.6 M | 14.2 M | 14.2 M | 14.2 M | 13.6 M | 12.8 M | 12.9 M | 12.8 M | 12.8 M | 17.5 M | 17.5 M | 17.5 M | 17.5 M | 8.06 M | 8.06 M | 8.06 M | 8.06 M | 5.66 M | 5.66 M | 5.66 M | 5.66 M | 6.99 M | 6.99 M | 6.99 M | 6.99 M |
Cash and Cash Equivalents |
1.35 M | 1.27 M | 2.25 M | 3.26 M | 4.78 M | 5.75 M | 4.01 M | 2.98 M | 2.17 M | 3.7 M | 2.28 M | 8.72 M | 9.81 M | 11 M | 13.3 M | 14.8 M | 14.5 M | 16 M | 17 M | 14.2 M | 14.2 M | 14.2 M | 14.2 M | 1.52 M | 1.52 M | 1.52 M | 1.52 M | 2 M | 743 K | 743 K | 743 K | 2.64 M | 2.64 M | 2.64 M | 2.64 M | 3.6 M | 3.6 M | 3.6 M | 3.6 M | 4.19 M | 4.19 M | 4.19 M | 4.19 M | 10.4 M | 10.4 M | 10.4 M | 10.4 M | 1.15 M | 1.15 M | 1.15 M | 1.15 M | 165 K | 165 K | 165 K | 165 K | 96.3 K | 96.3 K | 96.3 K | 96.3 K |
Book Value |
2.55 M | 3.34 M | 4.46 M | 5.83 M | 7.22 M | 7.95 M | 7.46 M | 8.01 M | 7.78 M | 7.92 M | 9.25 M | 10 M | 11.2 M | 9.87 M | 14.8 M | 16.2 M | 16 M | 17.6 M | 19 M | 16.1 M | 16.1 M | 16.1 M | 16.1 M | 1.63 M | 1.63 M | 1.63 M | 1.63 M | 1.53 M | 1.53 M | 1.53 M | 1.53 M | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 8.54 M | 8.54 M | 8.54 M | 13.6 M | 12.8 M | 12.9 M | 12.8 M | 12.8 M | 15 M | 17.5 M | 17.5 M | 17.5 M | 5.52 M | 5.5 M | 5.08 M | 4.64 M | 1.94 M | 5.66 M | 1.94 M | 1.94 M | 6.99 M | 6.99 M | 6.99 M | 6.99 M |
Total Shareholders Equity |
2.55 M | 3.34 M | 4.46 M | 5.83 M | 7.22 M | 7.95 M | 7.46 M | 8.01 M | 6.99 M | 7.7 M | 9.25 M | 10.2 M | 11.2 M | 12.7 M | 14.8 M | 16.4 M | 16 M | 17.6 M | 19 M | 16.2 M | 16.2 M | 16.2 M | 16.2 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.54 M | 1.54 M | 1.54 M | 1.54 M | 7.24 M | 7.24 M | 7.24 M | 7.24 M | 8.5 M | 8.5 M | 8.5 M | 8.5 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 14.6 M | 14.6 M | 14.6 M | 14.6 M | 5.52 M | 5.52 M | 5.52 M | 5.52 M | 1.94 M | 1.94 M | 1.94 M | 1.94 M | 1.94 M | 1.94 M | 1.94 M | 1.94 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Milestone Scientific , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Medical instruments
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Baxter International
BAX
|
$ 18.99 | 0.48 % | $ 9.68 B |  USA |
 |
Becton, Dickinson and Company
BDX
|
$ 200.87 | 0.22 % | $ 57.8 B | USA |
 |
BioLife Solutions
BLFS
|
$ 24.43 | -1.81 % | $ 1.13 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 4.79 | 2.35 % | $ 96.6 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 11.59 | -0.13 % | $ 2.36 B | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Alcon
ALC
|
$ 78.74 | -0.03 % | $ 40.4 B |  Schweiz |
 |
iRhythm Technologies
IRTC
|
$ 170.09 | 0.58 % | $ 5.31 B | USA |
 |
AtriCure
ATRC
|
$ 42.08 | 1.62 % | $ 1.98 B | USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
electroCore
ECOR
|
$ 4.81 | -0.21 % | $ 26.5 K | USA |
 |
Harvard Bioscience
HBIO
|
$ 0.76 | 1.78 % | $ 32.2 M | USA |
 |
AngioDynamics
ANGO
|
$ 13.12 | -2.42 % | $ 536 M | USA |
 |
The Cooper Companies
COO
|
$ 81.82 | -0.36 % | $ 16.3 B | USA |
 |
ICU Medical
ICUI
|
$ 147.72 | 0.34 % | $ 3.6 B | USA |
 |
Glaukos Corporation
GKOS
|
$ 109.57 | 0.31 % | $ 5.31 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 83.2 | -1.49 % | $ 4.19 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 9.24 | 0.33 % | $ 191 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Repro Med Systems
KRMD
|
$ 5.75 | -1.88 % | $ 262 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 83.51 | 0.18 % | $ 1.87 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 541.3 | -1.11 % | $ 192 B | USA |
 |
Masimo Corporation
MASI
|
$ 138.1 | -2.25 % | $ 7.36 B | USA |
 |
Merit Medical Systems
MMSI
|
$ 86.52 | -0.01 % | $ 5.04 B | USA |
 |
Microbot Medical
MBOT
|
$ 2.43 | 2.21 % | $ 24.8 M |  Israel |
 |
Nephros
NEPH
|
$ 5.08 | 2.24 % | $ 52.8 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
ResMed
RMD
|
$ 250.7 | -0.67 % | $ 36.6 B | USA |
 |
Envista Holdings Corporation
NVST
|
$ 21.79 | -1.58 % | $ 3.75 B | USA |
 |
OraSure Technologies
OSUR
|
$ 2.52 | -2.14 % | $ 188 M | USA |
 |
Pro-Dex
PDEX
|
$ 43.83 | 0.6 % | $ 144 M | USA |
 |
Pulse Biosciences
PLSE
|
$ 14.26 | 3.71 % | $ 685 M | USA |
 |
Predictive Oncology
POAI
|
$ 5.95 | 0.51 % | $ 32.4 M | USA |
 |
Repligen Corporation
RGEN
|
$ 156.65 | -3.1 % | $ 8.73 M | USA |
 |
Retractable Technologies
RVP
|
$ 0.83 | -0.31 % | $ 24.8 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 24.16 | -2.11 % | $ 1.19 B | USA |
 |
STERIS plc
STE
|
$ 251.01 | -0.59 % | $ 24.7 B | USA |
 |
Stereotaxis
STXS
|
$ 2.38 | -1.45 % | $ 192 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 125.81 | -1.13 % | $ 5.89 B | USA |
 |
Utah Medical Products
UTMD
|
$ 57.99 | 0.5 % | $ 210 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 266.92 | -2.06 % | $ 19.5 B | USA |